

## **DATASHEET**

Abbexa Ltd, Innovation Centre, Cambridge Science Park, Cambridge, CB4 0EY, UK Telephone: +44 (0) 1223 755950 - Fax: +44 (0) 1223 755951 - E-Mail: info@abbexa.com

## Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) CLIA Kit

Catalogue No.:abx495288



Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) CLIA Kit is a Sandwich CLIA Kit for use with Serum, plasma, tissue homogenates and other biological fluids.

Please note that this kit is also available as an ELISA Kit abx150793.

Target: Breast Cancer Anti-Estrogen Resistance 3 (BCAR3)

Reactivity: Human

Tested Applications: CLIA

Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user.

**Test Range:** 78.12 pg/ml - 5000 pg/ml

Sensitivity: < 27 pg/ml

**Validity:** The validity for this kit is 6 months.

Storage: Store at 2°C to 8°C upon receipt.

**Stability:** The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5% within

the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested

that the whole assay is performed by the same user throughout.

Standard Form: Lyophilized

ELISA Detection: Fluorometric

ELISA Type: Sandwich



## **DATASHEET**

Abbexa Ltd, Innovation Centre, Cambridge Science Park, Cambridge, CB4 0EY, UK Telephone: +44 (0) 1223 755950 - Fax: +44 (0) 1223 755951 - E-Mail: info@abbexa.com

**ELISA Data:** Quantitative

**Sample Type:** Serum, plasma, tissue homogenates and other biological fluids.

**Note:** This product is for research use only.

The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a

specific range, please contact us in advance or write your request in your order comments.

Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may

have different sequences or tertiary structures to the native protein.